Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody
Related Experiment Video
Updated: Dec 6, 2025
Silvia Martini1, Mariangela Figini2, Aurora Croce1
1Molecular Pharmacology Unit, Department of Applied Research and Technical Development, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
Abstract:
Triple-negative breast cancer (TNBC) is an aggressive disease with poor prognosis and limited therapeutic options. Recent advances in the immunotherapy field have enabled the development of new treatment strategies, among which the use of bispecific antibodies (BsAbs), able to redirect T cells against tumors, has shown promising results. In particular, a BsAb that uses TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) as a target was constructed and demonstrated good results in redirecting CD3+ T cells to kill TRAIL-R2-expressing TNBC cells. In the present study, we investigated whether treatment with selinexor, a selective inhibitor of nuclear export (SINE) targeting exportin-1/chromosome maintenance protein 1 (XPO1/CRM1), could potentiate the antitumor activity of this BsAb. In combination experiments, we found that selinexor-exposed TNBC cells exhibited greater growth inhibition when treated with the TRAIL-R2xCD3 BsAb than that expected by simple additivity. Similarly, the apoptosis rate in selinexor/TRAIL-R2xCD3 BsAb-treated TNBC cells was significantly higher than that observed after exposure to either single agent. Together, our results suggest that the combination of selinexor and TRAIL-R2xCD3 BsAb can be a viable anticancer strategy and indicate this treatment as a promising therapeutic option for TNBC patients.
Insights
Combining selinexor with a TRAIL-R2xCD3 bispecific antibody enhances T-cell-mediated killing of triple-negative breast cancer (TNBC) cells. This potent combination therapy significantly increases tumor cell death and growth inhibition in TNBC.
Area of Science:
- Immunotherapy
- Oncology
- Molecular Biology
Background:
- Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to its aggressive nature and limited treatment options.
- Bispecific antibodies (BsAbs) redirect T cells to target cancer cells, showing promise in immunotherapy.
- TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) targeted BsAbs have demonstrated efficacy against TNBC.
Purpose of the Study:
- To investigate the potential of selinexor, a selective inhibitor of nuclear export (SINE), to enhance the antitumor activity of a TRAIL-R2xCD3 bispecific antibody.
- To evaluate the combined efficacy of selinexor and the TRAIL-R2xCD3 BsAb in TNBC treatment.
Main Methods:
- In vitro combination experiments were conducted using TNBC cell lines.
- Cell growth inhibition was assessed in response to single-agent and combination treatments.
- Apoptosis rates were quantified in treated TNBC cells.
Main Results:
- Selinexor treatment potentiated the antitumor activity of the TRAIL-R2xCD3 BsAb, resulting in greater growth inhibition than additive effects.
- The combination therapy significantly increased the apoptosis rate in TNBC cells compared to either agent alone.
- TNBC cells expressing TRAIL-R2 were effectively targeted by the BsAb, with enhanced killing in the presence of selinexor.
Conclusions:
- The combination of selinexor and the TRAIL-R2xCD3 BsAb represents a promising therapeutic strategy for TNBC.
- This combination therapy demonstrates enhanced antitumor activity through increased T-cell-mediated cytotoxicity and apoptosis induction.
- Further investigation is warranted to explore this combination as a viable treatment option for patients with triple-negative breast cancer.
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
